抗炎症薬の世界市場-2023年～2030年

市場概要

抗炎症薬の世界市場は、2022年に877億米ドルに達し、2030年には1,701億米ドルに達する好成長が予測されています。抗炎症薬の世界市場は、2023～2030年の予測期間中に8.8%のCAGRを示すと予測されます。

抗炎症薬は、炎症を引き起こす体内の特定の分子を阻害することで作用します。抗炎症薬は、片頭痛、頭痛、関節リウマチ、捻挫、月経不快感などの様々な病気を治療します。

自己免疫疾患や呼吸器疾患の有病率の増加、パイプラインにおける新規治療法の発見、抗炎症薬の使用増加など、いくつかの要因が世界の抗炎症薬市場を牽引しています。さらに、従来の治療法よりも副作用の少ない、オーダーメイドで効果の高い抗炎症生物製剤が開発された結果、抗炎症薬の需要が急速に増加しています。

市場力学

技術の進歩が世界の抗炎症薬市場を牽引する見通し

標的ドラッグデリバリーシステム、新規薬剤製剤、新しい薬剤投与方法の開発などの技術の進歩が、世界の抗炎症薬市場を大きく成長させています。

例えば、UConn Pharmacyの研究者らは、長期間の持続的放出を可能にする長時間作用型注射NSAIDsとして知られる非ステロイド性抗炎症薬（NSAIDs）の画期的な投与技術を開発しました。

この進歩は、非ステロイド性抗炎症薬（NSAID）の長期使用に伴う悪影響を軽減または除去する可能性を提供するものです。これらの進歩は世界の抗炎症薬市場に大きな可能性をもたらし、患者の転帰を改善し、炎症性疾患の治療に革命をもたらす可能性があります。

世界の抗炎症薬市場は、厳しい規制当局の承認別制約に直面する可能性があります

新規抗炎症薬の市場導入には、規制当局の承認手続きが必要となるため、しばしば遅れが生じる。安全性、有効性、品質基準を示すために、新規の抗炎症薬を開発する製薬会社は包括的な前臨床試験と多くの段階の臨床試験を受けなければならないです。

これらの試験には、多数の患者を長期間にわたって募集し、モニタリングする必要があります。こうした理由から、世界の抗炎症薬市場は予測期間中に大きな抑制要因に直面することになります。

COVID-19影響分析

COVID-19は罹患者に炎症を引き起こす病気であるため、COVID-19の流行は抗炎症薬市場に好影響を与えると予想されます

COVID-19はβ型コロナウイルスSARS-CoV-2によって引き起こされ、炎症の増加とともに重症の肺炎を引き起こします。研究によれば、サイトカインストームがこれらの患者の死に大きく関与しています。重篤な炎症とサイトカインストームは、多くの臓器機能不全症候群、急性肺障害、急性呼吸窮迫症候群、その他の影響をもたらす可能性があります。その結果、COVID-19が誘発する炎症を治療するための抗炎症薬を製造する努力が高まっています。

ロシア・ウクライナ紛争分析

ロシアとウクライナの紛争は、世界の抗炎症薬産業に大きな影響を与えています。紛争は貿易力学を変化させ、サプライチェーン、原材料の価格、医薬品の入手可能性に影響を及ぼしています。特に東欧、欧州連合（EU）、東アジア・中央アジア、米国など、世界中で悪影響が予想されます。

紛争によってウクライナ経済は崩壊し、医薬品の製造・流通が大幅に減少し、価格も大幅に上昇しました。この危機は、非ステロイド性抗炎症薬の世界市場に影響を与え、価格選択の圧力をかけ、輸出入や貿易活動を変化させています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • テクノロジーの進歩
  • 抑制要因
    • 厳しい規制当局の承認
  • 機会
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 適応症別

• 関節炎
• 慢性閉塞性肺疾患（COPD）
• 多発性硬化症
• 炎症性腸疾患（IBD）
• 喘息
• 腱鞘炎
• その他

第8章 薬剤クラス別

• 抗炎症生物製剤
• 非ステロイド性抗炎症薬（NSAIDS）
• コルチコステロイド
• 免疫選択的抗炎症誘導体（IMSAID）
• その他

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Amgen Inc
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• AstraZeneca
• Merck & Co.
• GlaxoSmithKline
• Bristol-Myers Squibb
• F-Hoffmann-La-Roche
• Eli Lilly
• Sanofi
• Abbott Laboratories
• Boehringer Ingelheim GmbH

第13章 付録

Market Overview

The Global Anti-Inflammatory Drugs Market reached US$ 87.7 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 170.1 billion by 2030. The Global Anti-Inflammatory Drugs Market is expected to exhibit a CAGR of 8.8% during the forecast period 2023-2030.

Anti-inflammatory drugs act by inhibiting particular molecules in the body that cause inflammation. They treat various ailments such as migraines, headaches, rheumatoid arthritis, sprains, and menstruation discomfort.

Several factors drive the Global Anti-Inflammatory Market due to the increasing prevalence of autoimmune and respiratory disorders, the discovery of novel treatments in the pipeline, and the increased use of anti-inflammatory medications. Furthermore, the demand for anti-inflammatory drug has been quickly increasing as a result of the development of tailored and highly effective anti-inflammatory biologics, which have fewer adverse effects than traditional treatments.

Market Dynamics

The Advancements in Technology is Expected to Drive the Global Anti-Inflammatory Market

Technology advancements, such as targeted drug delivery systems, novel drug formulations, and the development of new drug administration methods, are driving considerable growth in the worldwide anti-inflammatory medications market.

For instance, UConn Pharmacy researchers have created a ground-breaking technology for administering nonsteroidal anti-inflammatory medicines (NSAIDs) known as long-acting injectable NSAIDs that allow sustained release over time.

This advancement offers the potential to lessen or eliminate the negative consequences associated with long-term NSAID use. These advances provide good possibilities for the global anti-inflammatory drugs market, potentially improving patient outcomes and revolutionizing the treatment of inflammatory disorders.

The Global Anti-Inflammatory Drugs Market May Face Constraints Due to the Stringent Regulatory Approvals

The extensive regulatory clearance procedure frequently causes delays in the introduction of new anti-inflammatory medications to the market. To show its safety, effectiveness, and quality standards, a pharmaceutical firm developing a novel anti-inflammatory medicine must undergo comprehensive preclinical investigations and numerous phases of clinical trials.

These studies entail recruiting and monitoring a large number of patients over a long period of time. Owing to this reason, the global anti-inflammatory drugs market will face a major restraint over the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic is expected to have a favourable effect on the market for anti-inflammatory drugs since the illness causes inflammation in those afflicted.

COVID-19 is caused by the beta coronavirus SARS-CoV-2, which can cause severe pneumonia with increased inflammation. According to studies, Cytokine storms play a substantial role in these individuals' deaths. Severe inflammation and cytokine storms can result in many organ dysfunction syndromes, acute lung injury, acute respiratory distress syndrome, and other effects. As a result, efforts to produce anti-inflammatory drugs to treat COVID-19-induced inflammation have risen.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war has substantially influenced the global anti-inflammatory drugs industry. The conflict has altered trade dynamics, affecting the supply chain, the pricing of raw materials, and the availability of pharmaceuticals. Negative consequences are expected all throughout the world, notably in Eastern Europe, the European Union, Eastern and Central Asia, and the United States.

The conflict has caused the Ukrainian economy to collapse, resulting in significant decreases in medicine manufacture and distribution and significant price rises. The crisis has influenced the worldwide market for nonsteroidal anti-inflammatory drugs, putting pressure on pricing choices and altering import/export and trade activities.

Segment Analysis

The Global Anti-Inflammatory Drugs Market is segmented based on indication, drug class, distribution channel, and region.

The Anti-Inflammatory Biologics Segment is Expected to Dominate the Global Anti-Inflammatory Drugs Market

In drug class, the anti-inflammatory biologics segment is projected to dominate the anti-inflammatory drugs market. It will account the highest market share of 34.3% due to their targeted delivery approach, enhanced efficacy, personalized medicine potential, and the increasing number of indications that are addressed by these biologics, making them a forefront runner.

Anti-inflammatory biologics are rapidly gaining a commanding position in the worldwide anti-inflammatory medicines industry. Biologics are medications generated from live organisms that target specific inflammatory pathways or substances in the body.

Many companies in the U.S. invest in biologics and its biosimilar to make it cost-effective for the people. For instance, in January 2023, AMJEVITA (adalimumab-atto), a biosimilar of Humira (adalimumab), was introduced by Amgen and is currently accessible in the United States.

In 2016, the US Food and Drug Administration (FDA) authorized AMJEVITA as the first biosimilar of Humira. It is a medication used by over a million individuals suffering from severe inflammatory illnesses. Therefore, owing to the above factor, the Global Anti-Inflammatory market is expected to fuel over the forecast period.

Geographical Analysis

North America Region Holds the Largest Market Share of the Global Anti-Inflammatory Drugs Market

North America is expected to hold a dominant position in the global anti-inflammatory drugs market, clinching a 38.7% share of the total market due to the growing elderly population, better healthcare spending, technological advancements, presence of major market players leading to drug development, and the advanced healthcare infrastructure.

Age-related illnesses, including osteoporosis, cardiovascular disease, and arthritis, become increasingly common. These ailments frequently entail persistent inflammation, which raises the demand for anti-inflammatory medications. For instance, according to World Health Organization 2022 report, by 2030, one out of every six persons in this world will be 60 or older.

The number of people aged 60 and more is expected to grow from 1 billion in 2020 to 1.4 billion by 2030. Therefore, the growing aging population is expected to dominate North America's global anti-inflammatory drugs market over the forecast period.

Competitive Landscape

The major global players in the market include: Amgen Inc, AstraZeneca, Merck & Co., GlaxoSmithKline, Bristol-Myers Squibb, F-Hoffmann-La-Roche, Eli Lilly, Sanofi, Abbot Laboratories, and Boehringer Ingelheim GmbH.

Why Purchase the Report?

• To visualize Global Anti-Inflammatory Drugs Market segmentation based on indication, drug class, distribution channel, and region- and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous global anti-inflammatory drugs market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Anti-Inflammatory Drugs Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Market Snippet By Indication
• 3.2. Market Snippet by Drug Class
• 3.3. Market Snippet by Distribution Channel
• 3.4. Market Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Advancements in technology
  • 4.1.2. Restraints
    • 4.1.2.1. Stringent regulatory approvals
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Post COVID-19 & Future Scenario
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Indication

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 7.1.2. Market Attractiveness Index, By Indication
• 7.2. Arthritis
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Chronic obstructive pulmonary disease (COPD)
• 7.4. Multiple Sclerosis
• 7.5. Inflammatory bowel disease (IBD)
• 7.6. Asthma
• 7.7. Tendonitis
• 7.8. Other

8. By Drug Class

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.1.2. Market Attractiveness Index, By Drug Class
• 8.2. Anti-Inflammatory Biologics
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Nonsteroidal anti-inflammatory drugs (NSAIDS)
• 8.4. Corticosteroids
• 8.5. Immune-selective anti-inflammatory derivative (IMSAID)
• 8.6. Others

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Amgen Inc*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. AstraZeneca
• 12.3. Merck & Co.
• 12.4. GlaxoSmithKline
• 12.5. Bristol-Myers Squibb
• 12.6. F-Hoffmann-La-Roche
• 12.7. Eli Lilly
• 12.8. Sanofi
• 12.9. Abbott Laboratories
• 12.10. Boehringer Ingelheim GmbH

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us